The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Effect of Universal Testing and Treatment on HIV Incidence — HPTN 071 (PopART)
Open accessAbstract
BACKGROUND: A universal testing and treatment strategy is a potential approach to reduce the incidence of human immunodeficiency virus (HIV) infection, yet previous trial results are inconsistent. METHODS: In the HPTN 071 (PopART) community-randomized trial conducted from 2013 through 2018, we randomly assigned 21 communities in Zambia and South Africa (total population, approximately 1 million) to group A (combination prevention intervention with universal antiretroviral therapy [ART]), group B (the prevention intervention with ART provided according to local guidelines [universal since 2016]), or group C (standard care). The prevention intervention included home-based HIV testing delivered by community workers, who also supported linkage to HIV care and ART adherence. The primary outcome, HIV incidence between months 12 and 36, was measured in a population cohort of approximately 2000 randomly sampled adults (18 to 44 years of age) per community. Viral suppression (<400 copies of HIV RNA per milliliter) was assessed in all HIV-positive participants at 24 months. RESULTS: The population cohort included 48,301 participants. Baseline HIV prevalence was 21% or 22% in each group. Between months 12 and 36, a total of 553 new HIV infections were observed during 39,702 person-years (1.4 per 100 person-years; women, 1.7; men, 0.8). The adjusted rate ratio for group A as compared with group C was 0.93 (95% confidence interval [CI], 0.74 to 1.18; P = 0.51) and for group B as compared with group C was 0.70 (95% CI, 0.55 to 0.88; P = 0.006). The percentage of HIV-positive participants with viral suppression at 24 months was 71.9% in group A, 67.5% in group B, and 60.2% in group C. The estimated percentage of HIV-positive adults in the community who were receiving ART at 36 months was 81% in group A and 80% in group B. CONCLUSIONS: A combination prevention intervention with ART provided according to local guidelines resulted in a 30% lower incidence of HIV infection than standard care. The lack of effect with universal ART was unanticipated and not consistent with the data on viral suppression. In this trial setting, universal testing and treatment reduced the population-level incidence of HIV infection. (Funded by the National Institute of Allergy and Infectious Diseases and others; HPTN 071 [PopArt] ClinicalTrials.gov number, NCT01900977.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Prevention of HIV-1 infection with early antiretroviral therapy.
Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., Hakim, J. G., Kumwenda, J., Grinsztejn, B., Pilotto, J. H. S., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1105243 · Cited by 6,873
Self-citationInitiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection
The INSIGHT START Study Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1506816 · Cited by 2,798
Granich, R. M., Gilks, C. F., Dye, C., De Cock, K. M., & Williams, B. G. (2009) · The Lancet · doi:10.1016/s0140-6736(08)61697-9 · Cited by 1,988
Antiretroviral therapy for the prevention of HIV-1 transmission.
Cohen, M. S., Chen, Y. Q., McCauley, M., Gamble, T., Hosseinipour, M. C., Kumarasamy, N., Hakim, J. G., Kumwenda, J., Grinsztejn, B., Pilotto, J. H. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1600693 · Cited by 1,700
Self-citationRodger, A. J., Cambiano, V., Bruun, T., Vernazza, P., Collins, S., van Lunzen, J., Corbelli, G. M., Estrada, V., Geretti, A. M., Beloukas, A., et al. (2016) · JAMA · doi:10.1001/jama.2016.5148 · Cited by 1,431
A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa
The TEMPRANO ANRS 12136 Study Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507198 · Cited by 1,242
Tanser, F., Bärnighausen, T., Grapsa, E., Zaidi, J., & Newell, M.-L. (2013) · Science · doi:10.1126/science.1228160 · Cited by 796
HIV Viral Load and Transmissibility of HIV Infection: Undetectable Equals Untransmittable
Eisinger, R. W., Dieffenbach, C. W., & Fauci, A. S. (2019) · JAMA · doi:10.1001/jama.2018.21167 · Cited by 753
Eaton, J. W., Johnson, L. F., Salomon, J. A., Bärnighausen, T., Bendavid, E., Bershteyn, A., Bloom, D. E., Cambiano, V., Fraser, C., Hontelez, J. A. C., et al. (2012) · PLoS Medicine · doi:10.1371/journal.pmed.1001245 · Cited by 395
Self-citationA Practical Guide to Cluster Randomised Trials in Health Services Research
Eldridge, S., & Kerry, S. (2012) · Wiley eBooks · doi:10.1002/9781119966241 · Cited by 351
Iwuji, C. C., Orne-Gliemann, J., Larmarange, J., Balestre, E., Thiebaut, R., Tanser, F., Okesola, N., Makowa, T., Dreyer, J., Herbst, K., et al. (2018) · The Lancet HIV · doi:10.1016/s2352-3018(17)30205-9 · Cited by 225
Hayes, R., Ayles, H., Beyers, N., Sabapathy, K., Floyd, S., Shanaube, K., Bock, P., Griffith, S., Moore, A., Watson-Jones, D., et al. (2014) · Trials · doi:10.1186/1745-6215-15-57 · Cited by 220
Self-citationHIV Testing and Treatment with the Use of a Community Health Approach in Rural Africa
Havlir, D. V., Balzer, L. B., Charlebois, E. D., Clark, T. D., Kwarisiima, D., Ayieko, J., Kabami, J., Sang, N., Liegler, T., Chamie, G., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1809866 · Cited by 212
Universal Testing, Expanded Treatment, and Incidence of HIV Infection in Botswana
Makhema, J., Wirth, K. E., Pretorius Holme, M., Gaolathe, T., Mmalane, M., Kadima, E., Chakalisa, U., Bennett, K., Leidner, J., Manyake, K., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812281 · Cited by 205
Granich, R., Crowley, S., Vitoria, M., Smyth, C., Kahn, J. G., Bennett, R., Lo, Y.-R., Souteyrand, Y., & Williams, B. (2010) · Current Opinion in HIV and AIDS · doi:10.1097/coh.0b013e32833a6c32 · Cited by 200
Hargreaves, J., Delany‐Moretlwe, S., Hallett, T. B., Johnson, S., Kapiga, S., Bhattacharjee, P., Dallabetta, G., & Garnett, G. P. (2016) · The Lancet HIV · doi:10.1016/s2352-3018(16)30063-7 · Cited by 186
Self-citationInterventions to strengthen the HIV prevention cascade: a systematic review of reviews
Krishnaratne, S., Hensen, B., Cordes, J. L., Enstone, J. E., & Hargreaves, J. (2016) · The Lancet HIV · doi:10.1016/s2352-3018(16)30038-8 · Cited by 179
Self-citationChang, L. W., Serwadda, D., Quinn, T. C., Wawer, M. J., Gray, R. H., & Reynolds, S. J. (2012) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(12)70273-6 · Cited by 165
Hayes, R., Floyd, S., Schaap, A., Shanaube, K., Bock, P., Sabapathy, K., Griffith, S., Donnell, D. J., Piwowar‐Manning, E., El‐Sadr, W., et al. (2017) · PLoS Medicine · doi:10.1371/journal.pmed.1002292 · Cited by 124
Self-citationHighly active antiretroviral treatment for the prevention of HIV transmission
Granich, R., Crowley, S., Vitória, M., Lo, Y.-R. J., Souteyrand, Y., Dye, C., Gilks, C. F., Guerma, T., Cock, K. M. D., & Williams, B. G. (2010) · Journal of the International AIDS Society · doi:10.1186/1758-2652-13-1 · Cited by 122
Cori, A., Ayles, H., Beyers, N., Schaap, A., Floyd, S., Sabapathy, K., Eaton, J. W., Hauck, K., Smith, P., Griffith, S., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0084511 · Cited by 106
Self-citationTanser, F. C., Vandormael, A. M., Cuadros, D. F., Phillips, A. N., de Oliveira, T., Tomita, A. M., Bärnighausen, T., & Pillay, D. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aam8012 · Cited by 94
Floyd, S., Ayles, H., Schaap, A., Shanaube, K., Macleod, D., Phiri, M. M., Griffith, S., Bock, P., Beyers, N., Fidler, S. J., et al. (2018) · PLoS ONE · doi:10.1371/journal.pone.0197904 · Cited by 47
Self-citationFayorsey, R. N., Wang, C., Chege, D., Reidy, W. J., Syengo, M., Owino, S. O., Koech, E., Sirengo, M., Hawken, M. P., & Abrams, E. J. (2018) · JAIDS Journal of Acquired Immune Deficiency Syndromes · doi:10.1097/qai.0000000000001882 · Cited by 26
Cited by
Achieving the 95 95 95 targets for all: A pathway to ending AIDS
Frescura, L., Godfrey-Faussett, P., Feizzadeh, A., El-Sadr, W., Syarif, O., Ghys, P. D., & on behalf of the 2025 testing treatment target Working Group (2022) · PLOS ONE · doi:10.1371/journal.pone.0272405 · Cited by 442
Self-citationPachankis, J. E., Harkness, A., Maciejewski, K. R., Behari, K., Clark, K. A., McConocha, E., Winston, R., Adeyinka, O., Reynolds, J., Bränström, R., et al. (2022) · Journal of Consulting and Clinical Psychology · doi:10.1037/ccp0000724 · Cited by 112
Jamil, M. S., Eshun-Wilson, I., Witzel, T. C., Siegfried, N., Figueroa, C., Chitembo, L., Msimanga-Radebe, B., Pasha, M. S., Hatzold, K., Corbett, E., et al. (2021) · eClinicalMedicine · doi:10.1016/j.eclinm.2021.100991 · Cited by 96
Khan, S., Spiegelman, D., Walsh, F., Mazibuko, S., Pasipamire, M., Chai, B., Reis, R., Mlambo, K., Delva, W., Khumalo, G., et al. (2020) · Journal of the International AIDS Society · doi:10.1002/jia2.25610 · Cited by 32
Floyd, S., Klinkenberg, E., de Haas, P., Kosloff, B., Gachie, T., Dodd, P. J., Ruperez, M., Wapamesa, C., Burnett, M. J., Kalisvaart, N., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-058195 · Cited by 29
Self-citation
Metadata
- Authors
- Hayes, R. J., Donnell, D., Floyd, S., Mandla, N., Bwalya, J., Sabapathy, K., Yang, B., Phiri, M., Schaap, A., Eshleman, S. H., Piwowar-Manning, E., Kosloff, B., James, A., Skalland, T., Wilson, E., Emel, L., Macleod, D., Dunbar, R., Simwinga, M., Makola, N., Bond, V., Hoddinott, G., Moore, A., Griffith, S., Deshmane Sista, N., Vermund, S. H., El-Sadr, W., Burns, D. N., Hargreaves, J. R., Hauck, K., Fraser, C., Shanaube, K., Bock, P., Beyers, N., Ayles, H., & Fidler, S.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-07-18
- Volume
- 381
- Issue
- 3
- Pages
- 207-218
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2961360820
- Cited by
- 337
- References
- 24
- FWCI
- 36.72
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.